

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BOREA ET AL.

Group Art Unit: 1618

Serial No.: 10/603,406

Examiner: Gembah, Shirley V.

Filed: June 24, 2003

Attorney Docket No.: PAT-0040-US-NP2

For: ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A₃
ANTAGONISTS

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Conf. No.: 4184

PETITION FOR EXTENSION OF TIME

Sir:

It is respectfully requested, pursuant to 37 CFR § 1.136(a), that the time for the response to the Office communication dated November 17, 2008 to be extended for a period of one month from November 28, 2008, the date set forth in the final rejection, up to and including December 28, 2008 to permit the filing of a continuation application.

Please charge Deposit Account No. 50-3706 in the name of King Pharmaceuticals, Inc. in the amount of \$ 130 for payment of the extension fee. The Commissioner is hereby authorized to charge any additional fees under 37 CFR § 1.17 which may be required, or credit any overpayment, to Deposit Account No. 50-3706 in the name of King Pharmaceuticals, Inc.

Respectfully submitted,



Paivi Kukkola
(Reg. No. 50,499)

King Pharmaceuticals, Inc.
400 Crossing Boulevard
Bridgewater, NJ 08807
Tel: (908) 429-6000 ext 58964

Date: December 18, 2008